Corcept Therapeutics (NASDAQ:CORT) Given New $110.00 Price Target at Canaccord Genuity Group

Corcept Therapeutics (NASDAQ:CORT) had its price target hoisted by Canaccord Genuity Group from $100.00 to $110.00 in a research note issued to investors on Thursday morning,Benzinga reports. Canaccord Genuity Group currently has a buy rating on the biotechnology company’s stock.

A number of other analysts also recently issued reports on CORT. Weiss Ratings reissued a “hold (c)” rating on shares of Corcept Therapeutics in a research report on Monday, December 29th. Wolfe Research upgraded shares of Corcept Therapeutics from an “underperform” rating to a “peer perform” rating in a research note on Thursday. Truist Financial upgraded Corcept Therapeutics to a “strong-buy” rating in a research report on Wednesday. UBS Group began coverage on shares of Corcept Therapeutics in a research report on Tuesday, December 16th. They issued a “neutral” rating and a $95.00 target price for the company. Finally, HC Wainwright reduced their price target on shares of Corcept Therapeutics from $67.00 to $60.00 and set a “buy” rating on the stock in a research report on Wednesday. One analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Corcept Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $77.67.

Corcept Therapeutics Trading Down 4.8%

Shares of CORT stock opened at $38.53 on Thursday. The company has a market capitalization of $4.10 billion, a price-to-earnings ratio of 46.99 and a beta of 0.29. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.85 and a current ratio of 2.92. The company has a 50-day simple moving average of $37.47 and a two-hundred day simple moving average of $61.00. Corcept Therapeutics has a 52-week low of $28.66 and a 52-week high of $117.33.

Corcept Therapeutics (NASDAQ:CORT) last issued its quarterly earnings results on Tuesday, February 24th. The biotechnology company reported $0.20 EPS for the quarter, missing analysts’ consensus estimates of $0.33 by ($0.13). Corcept Therapeutics had a net margin of 12.96% and a return on equity of 15.19%. The business had revenue of $202.13 million for the quarter, compared to analysts’ expectations of $254.94 million. During the same period in the previous year, the business posted $0.26 earnings per share. The business’s revenue was up 11.1% compared to the same quarter last year. Research analysts anticipate that Corcept Therapeutics will post 1.36 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, insider William Guyer sold 11,767 shares of the firm’s stock in a transaction on Friday, March 20th. The stock was sold at an average price of $36.01, for a total value of $423,729.67. Following the completion of the sale, the insider owned 2,231 shares of the company’s stock, valued at $80,338.31. This trade represents a 84.06% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director G Leonard Baker, Jr. bought 100,000 shares of the business’s stock in a transaction dated Tuesday, March 17th. The shares were bought at an average cost of $33.14 per share, for a total transaction of $3,314,000.00. Following the purchase, the director directly owned 1,146,631 shares in the company, valued at approximately $37,999,351.34. This represents a 9.55% increase in their position. The SEC filing for this purchase provides additional information. Insiders sold 60,000 shares of company stock valued at $2,241,035 in the last ninety days. 20.80% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Corcept Therapeutics

Hedge funds have recently bought and sold shares of the business. Advisory Services Network LLC bought a new stake in shares of Corcept Therapeutics in the 3rd quarter worth approximately $25,000. Clearstead Advisors LLC increased its holdings in Corcept Therapeutics by 163.6% in the 3rd quarter. Clearstead Advisors LLC now owns 311 shares of the biotechnology company’s stock worth $26,000 after buying an additional 193 shares in the last quarter. Hantz Financial Services Inc. grew its stake in shares of Corcept Therapeutics by 598.5% in the third quarter. Hantz Financial Services Inc. now owns 461 shares of the biotechnology company’s stock worth $38,000 after acquiring an additional 395 shares during the period. Larson Financial Group LLC raised its stake in Corcept Therapeutics by 2,326.3% during the 3rd quarter. Larson Financial Group LLC now owns 461 shares of the biotechnology company’s stock valued at $38,000 after buying an additional 442 shares during the last quarter. Finally, Gould Capital LLC increased its position in Corcept Therapeutics by 50.0% during the third quarter. Gould Capital LLC now owns 600 shares of the biotechnology company’s stock valued at $50,000 after acquiring an additional 200 shares during the last quarter. Institutional investors own 93.61% of the company’s stock.

More Corcept Therapeutics News

Here are the key news stories impacting Corcept Therapeutics this week:

• Positive Sentiment: FDA approval of Lifyorli (relacorilant) plus nab‑paclitaxel — the regulatory win is the primary commercial catalyst and triggered the recent multi‑day rally due to survival benefit data and earlier‑than‑expected decision. FDA Approves (BusinessWire)
• Positive Sentiment: Analyst/firm support: multiple firms raised or reiterated positive views (Truist to “strong‑buy”, Canaccord price target increase reported, HC Wainwright kept a Buy rating), which supports upside potential as the market prices in Lifyorli’s commercial opportunity. Analyst Coverage (Benzinga)
• Positive Sentiment: Insider confidence signal: market commentary highlighted a mid‑March purchase by a director (~100,000 shares) that likely helped amplify bullish positioning ahead of the approval. Insider Buy Analysis (QuiverQuant)
• Neutral Sentiment: Market structure/volatility: trading was temporarily halted (LULD pause) and the name has posted very large intraday moves as investors re‑price the company; expect elevated volume and short‑term volatility. Market Reaction Coverage (Reuters)
• Negative Sentiment: Multiple securities‑class‑action firms have filed/issued alerts alleging misstatements tied to prior FDA issues and patent litigation — several firms are seeking lead plaintiffs and note an April 21, 2026 deadline; these suits create tangible legal and financial overhang. Hagens Berman Alert (GlobeNewswire)
• Negative Sentiment: Recent insider selling: Corcept disclosed a sale by William Guyer (11,767 shares on Mar 20), which may be viewed negatively by some investors despite offsetting director purchases. Insider Sale SEC Filing

About Corcept Therapeutics

Corcept Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing drugs that modulate the effects of cortisol, a hormone implicated in a range of severe metabolic, oncologic and psychiatric disorders. The company’s scientific platform centers on selectively targeting the glucocorticoid receptor to counteract the harmful consequences of excess cortisol, a strategy designed to address diseases with significant unmet medical needs.

The company’s flagship marketed product, Korlym (mifepristone), is approved in the United States for the treatment of hyperglycemia secondary to Cushing’s syndrome in patients who have type 2 diabetes or glucose intolerance and are not candidates for surgery.